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Helicobacter pylori is the most important carcinogen for gastric adenocarcinoma. Bacterial virulence factors are essential players in
modulating the immune response involved in the initiation of carcinogenesis in the stomach; host genetic factors contribute to the
regulation of the inflammatory response and to the aggravation of mucosal damage. In terms of environmental factors, salt intake
and smoking contribute to the development of lesions. Various therapeutic schemes are proposed to eradicate H. pylori infection,
which could potentially prevent gastric cancer, offering the greatest benefit if performed before premalignant changes of the gastric
mucosa have occurred.
1. Introduction
The first isolation of Helicobacter pylori in the 1980s by
Marshall and Warren [1] brought to the medical and scien-
tific communities a new understanding of the pathogenesis
of diseases that affect the digestive tract. Since then, H.
pylori infection has been associated with the development
of acute and chronic gastritis, atrophic gastritis, peptic ulcer
disease, gastric mucosa-associated lymphoid tissue (MALT)
lymphoma, and gastric adenocarcinoma [2–4].
All patients with H. pylori infection have histological
gastritis, which corresponds to classical chronic gastritis
and is characterized by the infiltration of neutrophils and
other inflammatory cells. However, most patients are asymp-
tomatic for life, while only some will come to develop a
digestive disease [5].
Furthermore, when the relationship between H. pylori
infection and chronic gastritis was established, investigators
began to take interest in the causal role of the bacterium
in gastric cancer [6]. On the basis of numerous subsequent
epidemiological studies, H. pylori infection was shown to be
associated with an increased risk of gastric adenocarcinoma
development [5, 7]. Evidence that the presence of H. pylori
increases the risk of developing gastric cancer through atro-
phy and intestinal metaplasia has also been reported [8,
9], suggesting that H. pylori-positive patients develop these
conditions in greater proportion than control subjects. Con-
sequently, in 1994, the World Health Organization’s Inter-
national Agency for Research on Cancer concluded that H.
pylori has a causal link with gastric carcinogenesis and was
defined as a type I carcinogen, a definite human carcinogen
[10].
It is known that gastric cancer involves the interaction
of three major factors: the agent (in the great part of the
cases, H. pylori) and its pathogenicity, the characteristics of
the host, and the external environment [10–14].
Specifically regarding H. pylori infection, there are some
studies indicating that the eradication of the microorganisms
in the system could reduce the incidence of gastric cancer
in patients without precancerous lesions or, when lesions
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are present, that the eradication may or may not reduce
this incidence [15]. Also, when the eradication is done after
endoscopic mucosal resection in patients with early gas-
tric adenocarcinoma, it could decrease the recurrence of
metachronous gastric cancer in some patients [16].
Based on these observations, in this paper, we will
attempt to provide a comprehensive overview of the prin-
cipal concepts in the management of H. pylori infection, the
lines of treatment and the importance of eradication of this
bacterium in precancerous lesions and in early gastric cancer.
2. Management Guidelines
Various guidelines for the management of H. pylori infection
worldwide are available. Among these, the latest ones are
the “Maastricht III Consensus Report” (2005) [17], the
“American College of Gastroenterology Guideline on the
Management of Helicobacter pylori Infection” (2007) [18],
and the “Second Asia-Pacific Consensus Guidelines for
Helicobacter pylori Infection” (2009) [19].
Generally, the eradication of H. pylori in adults is
recommended when the bacterium is present in the gastric
mucosa. However, a discussion may arise about whether
or not to recommend specific treatment in asymptomatic
individuals that receive positive diagnoses for H. pylori in
routine exams. In these cases, patients should be advised
about the therapy, the adverse effects resulting from the use
of the chosen medications, and the importance of H. pylori
eradication in order to prevent some gastric diseases, such as
peptic ulcer disease and gastric cancer. The same approach
should be taken with respect to patients with functional
dyspepsia. H. pylori eradication offers modest but significant
benefits in these patients [20], and economic modeling
suggests that this benefit is cost effective [21].
Nowadays, eradication of H. pylori is recommended
for patients with gastroduodenal ulcers, MALT lymphoma,
in individuals with chronic use of nonsteroidal anti-
inflammatory drugs (NSAIDs), and proton pump inhibitors
(PPIs), in patients with atrophic gastritis and erosive duo-
denitis and in cases of gastric adenocarcinoma subjected
to surgical treatment. First-degree relatives of patients with
early or advanced distal gastric adenocarcinoma have to be
evaluated for H. pylori, and those who test positive have to be
submitted to eradication treatment.
As for gastroesophageal reflux disease, eradication of H.
pylori does not cause it and does not exacerbate symptoms in
patients with it either when untreated or in those receiving
PPI maintenance treatment [17, 22]. International consensus
statements diverge, with European [17, 23] and Canadian
[24] guidelines recommending treatment and US guidelines
not recommending treatment. In the Asia-Pacific region,
where reflux disease is less common while ulcer disease and
gastric cancer are more common, it is recognized that the
likelihood of and benefit in treating H. pylori infection will
be commensurately greater [19].
Furthermore, among the extradigestive diseases that have
been associated with H. pylori infection, the eradication
of the bacterium is recommended in patients with unex-
plained iron deficiency anemia and in patients with chronic
idiopathic thrombocytopenic purpura, when all other
known causes have been carefully excluded [17, 23].
3. Treatment
After a long evaluation period for multiple therapeutic regi-
mens for the eradication of H. pylori in infected individuals,
testing single medication regimens as well as the association
of two, three or four medications, some conclusions were
reached, among them that treatments should use at least
three associated drugs.
Knowledge about the structural characteristics and the
pharmacokinetics of each chosen drug is also important. H.
pylori has a thick glycocalyx that partially inhibits the drug’s
action, which is also hampered by the bacterium’s adherence
to the gastric epithelium. Furthermore, it is important that
each medication that acts directly on the bacterium be able
to dissolve rapidly in the stomach and remain stable across
a wide pH range, especially in an acidic environment. It
is also necessary that the active substance has appropriate
dimensions and ionic charge in order to allow it to enter
into the mucous layer and come close to the gastric mucosa.
Moreover, the medications with systemic action have to be
absorbed by the stomach and small intestine in order to be
secreted by the gastric mucosa.
Included in the therapeutic regimen, gastric acid secre-
tion inhibitors contribute to increase H. pylori eradication
rates. They can also relieve the adverse effects of other drugs
and, consequently, help to eliminate pain symptoms more
quickly. Furthermore, these drugs probably facilitate the bac-
tericidal action of antimicrobials by increasing intragastric
pH. In turn, the proton pump inhibitors (e.g. omeprazole,
lansoprazole, and pantoprazole) have a bacteriostatic effect
and cause the increase of the half-life of some antimicrobial
drugs in plasma.
Therapeutic options usually include clarithromycin, met-
ronidazole (or tinidazole), amoxicillin, furazolidone, tetra-
cycline (tetracycline phosphate complex, oxytetracycline,
and doxycycline), colloidal bismuth subcitrate, ranitidine
bismuth citrate (H2 receptor antagonist), and a PPI (omepra-
zole, lanzoprazole, or pantoprazole), along with other anti-
microbial agents.
Table 1 shows the main recommended regimens for H.
pylori eradication, including the most used regimens with
clarithromycin and amoxicilin with a PPI, and the most
recent therapies, as levofloxacin-based triple therapy, the
levofloxacin-based quadruple therapy, and the rifabutin-
based triple therapy. Usually, the duration of treatment is
seven to ten days but may reach up to 14 days, as appropriate.
According to the “Maastricht III Consensus Report” [17],
both three- and four-drug regimens are considered first-
line treatments. Standard triple therapy consisting of a PPI,
clarithromycin, and amoxicillin or metronidazole is more
successful if extended to more than seven days. Furthermore,
increased resistance to antibiotics used in the PPI triple
therapy, a phenomenon that has been observed worldwide,
needs to be considered in the selection of treatment. For
instance, the increase of clarithromycin resistance has been
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Table 1: Recommended regimens for the treatment of H. pylori infection in adults.
Treatment duration
(days)
Recommended regimens (all drugs administered orally)
7–10 Clarithromycin (500 mg, b.i.d.) + amoxicillin (1 g, b.i.d.) + ranitidine bismuth citrate (400 mg, b.i.d.)
7–10
Clarithromycin (500 mg, b.i.d.) + amoxicillin (1 g, b.i.d.) + ranitidine bismuth citrate (400 mg, b.i.d.) + omeprazole
(20 mg, b.i.d.) [or lanzoprazole (30 mg, b.i.d.) or pantoprazole (40 mg, b.i.d.)]
14
Metronidazole (400 to 500 mg, t.i.d. or q.i.d.) + colloidal bismuth subcitrate (120 mg, q.i.d.) + tetracycline (basic
phosphate or oxytetracycline) (500 mg, q.i.d.)
7–10
Metronidazole (400 to 500 mg, b.i.d. or t.i.d.) + amoxicillin (500 mg, b.i.d. or t.i.d.) + omeprazole (20 mg, b.i.d.)
[or lanzoprazole (30 mg, b.i.d.) or pantoprazole (40 mg, b.i.d.)]
4–7
Metronidazole (400 to 500 mg, t.i.d. or q.i.d.) + colloidal bismuth subcitrate (120 mg, q.i.d.) + tetracycline (basic
phosphate or oxytetracycline) (500 mg, q.i.d.) + omeprazole (20 mg, b.i.d.) [or lanzoprazole (30 mg, b.i.d.) or
pantoprazole (40 mg, b.i.d.)]
7 Clarithromycin (500 mg, b.i.d.) + metronidazole (400 to 500 mg, b.i.d.) + ranitidine bismuth citrate (400 mg, b.i.d.)
7
Clarithromycin (500 mg, b.i.d.) + metronidazole (400 to 500 mg, b.i.d.) + omeprazole (20 mg, b.i.d.) [or
lanzoprazole (30 mg, b.i.d.) or pantoprazole (40 mg, b.i.d.)]
7 PPI (standard dose, q.d.) + clarithromycin (500 mg, b.i.d.) + furazolidone (200 mg, b.i.d.)∗
7 PPI (standard dose, q.d.) + furazolidone (200 mg, t.i.d.) + tetracycline (500 mg, q.i.d.)∗
7
Bismuth (standard dose, b.i.d.) + tetracycline (500 mg, b.i.d.) + furazolidone (200 mg, b.i.d.) + PPI (standard dose,
b.i.d.) or ranitidine (standard dose, b.i.d.)∗
10 Levofloxacin (500 mg, q.d.) + amoxicillin (1 g, b.i.d.) + PPI (standard dose, b.i.d.)
10
Levofloxacin (500 mg, q.d.) + amoxicillin (500 mg, q.i.d.) + PPI (standard dose, b.i.d.) + bismuth (standard dose,
q.i.d.)
14 Rifabutin (150 mg, b.i.d.) + amoxicillin (500 mg, b.i.d.) + PPI (standard dose, b.i.d.)
∗Treatments used in Brazilian patients.
found to be one of the main risk factors for treatment failure
in most countries [25, 26].
Recently, sequential treatment consisting of five days of
a PPI plus amoxicillin, followed by five additional days of
a PPI plus clarithromycin and tinidazole, has been shown
to be better than the combination of a PPI plus amoxicillin
and clarithromycin for seven days [27, 28]. Novel first-line
anti-H. pylori therapies in 2011 include sequential therapy,
concomitant quadruple therapy, hybrid (dual-concomitant)
therapy, and bismuth-containing quadruple therapy.
Moreover, in cases of patients for whom there was a
failure of the standard triple therapy, a bismuth-containing
quadruple therapy comprising a PPI, bismuth, tetracycline,
and metronidazole can be employed as rescue treatment.
Triple therapy combining a PPI, levofloxacin, and amoxi-
cillin has been proposed as an alternative to the standard res-
cue therapy. This salvage regimen can achieve a higher eradi-
cation rate than bismuth-containing quadruple therapy in
some regions and has fewer adverse effects.
Levofloxacin-based triple therapy consisting of lev-
ofloxacin (500 mg, once daily), amoxicillin (1g, twice daily),
and a PPI (standard dose, twice daily) represents an en-
couraging strategy for second-line therapy. The second-line
therapy for patients who fail to eradicate H. pylori with the
new first-line therapies (such as sequential therapy, concomi-
tant therapy, or hybrid therapy) remains unclear [29]. Mean-
while, a recent study showed that a levofloxacin-based triple
therapy with lanzoprazole (30 mg, twice daily), levofloxacin
(250 mg, twice daily), and amoxicillin (1g, twice daily)
achieved a high eradication rate in patients who had failed
to clear H. pylori with sequential therapy [29, 30].
With respect to the third-line therapy, the Maastricht III
Consensus Report recommends the use of bacterial cultures
with antimicrobial sensitivity tests to select antibiotics for
third-line regimens [17]. The antituberculous agent Rifa-
butin (150 mg, twice a day) is an option that can be admin-
istered with a PPI (standard dose, twice a day) and amoxi-
cillin (1 g, twice a day) for ten to 14 days to eradicate H. pylori
[31]. However, it has to be considered that serious adverse
events can occur with rifabutin therapy, in addition to the
development of more resistant strains of Mycobacterium
tuberculosis and Mycobacterium avium [29].
Another possible treatment is the use of furazolidone,
with a PPI and clarithromycin or tetracycline, regimens that
have been utilized in Brazil. However, due to the possible
genotoxic and carcinogenetic effects, furazolidone use is not
approved in developed countries [32, 33].
Finally, considering the various and numerous therapeu-
tic regimens and the differences in the eradication rates in
different countries and even in regions within a country, it
is essential to use medications that have been tested and that
have been proven effective for the target population.
4. H. pylori Eradication and Prevention of
Gastric Cancer
4.1. Gastric Cancer and Its Classification. Gastric cancer
remains a major global health problem [34] and, despite the
decreasing incidence and mortality rates observed worldwide
over the last 50 years, it still ranks as a leading cause of cancer-
related deaths in many parts of the world [35]. Because the
symptoms are often absent or nonspecific in the early stages
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of the disease, diagnosis of gastric cancer is usually made in
advanced stages, when curative options are limited [36].
The vast majority of gastric cancers are adenocarcino-
mas, which can be generally divided into two types: the
intestinal and the diffuse [37], which correspond, respec-
tively, to the well-differentiated type and to the poorly-dif-
ferentiated type in the Japanese classification [5].
The diffuse type is often associated with familial distribu-
tion and hereditary genetic alterations [38] and is developed
in the stomach following chronic inflammation, especially
in the cardia [35]. The causative germ-line mutation has
been identified to be CDH-1, the e-cadherin gene, and this
mutation represents an initial step in the process of down-
stream gene activation leading towards further increases in
proliferation and cancer formation [39].
The intestinal type is thought to be preceded by a
sequence of precursor lesions [40], the basic components
of which are chronic inflammation of the gastric mucosa,
which slowly progresses through the premalignant stages
of atrophic gastritis, intestinal metaplasia, and dysplasia to
gastric cancer [41]. While most studies claim that H. pylori
infection is only related to distal gastric cancer, a high preva-
lence in patients with proximally located adenocarcinomas
has recently been demonstrated [39]. Approximately 80% of
patients with proximal gastric cancer reveal positive evidence
for actual or past infection with H. pylori if correct allocation
of the primary tumor is performed, and adenocarcinomas of
the distal esophagus are strictly excluded [42].
Finally, the risk for gastric carcinogenesis by H. pylori
infection is equal in the intestinal and diffuse types of gastric
cancer [42, 43].
4.2. Early and Advanced Gastric Adenocarcinomas. Patients
diagnosed in an early stage of the cancer present an excellent
prognosis, with a five-year survival rate greater than 90%.
In cases with advanced lesions, gastric cancer carries a poor
prognosis, with an overall five-year survival rate of less than
20% [44].
Early gastric cancer is defined as an adenocarcinoma
that is confined to the mucosa or submucosa, irrespective
of lymph-node invasion. Part of early gastric cancers is
believed to go through a life cycle consisting of ulcerations
[45]. Nevertheless, some early lesions rapidly progress to
advanced stages, and these cases comprise one of the princi-
pal questions concerning gastric carcinogenesis.
Advanced gastric cancer, in turn, is defined as one
that infiltrates the muscle layer along with all the other
various layers of tissue [46]. Concerning the differences
between the early and advanced stages of the disease, research
has suggested that there is a biological continuum from
benign disease to early, followed by advanced cancer. The
point at which this sequence becomes irreversible has yet
to be established [45]. Additionally, some questions about
the development of the cancer remain unanswered: why
would any tumor remain at an early stage for years without
treatment while others become advanced in a short time?
Have H. pylori virulence factors influenced this alteration?
What about the host characteristics and environmental
factors?
As written before, gastric carcinogenesis involves the
interaction between an etiologic agent (for the most part, H.
pylori), host characteristics, and the external environment.
4.2.1. H. pylori Virulence Factors. The strain-specific genes
found in the comparison of sequenced strains are consistent
with earlier studies that demonstrated the high diversity
of the H. pylori genome [47–49]. Consequently, this high
level of genetic diversity can be an important factor in its
adaptation to the host stomach and for the clinical outcome
of the infection although this aspect remains unclear.
Many virulence genes of H. pylori have been reported
to determine clinical outcomes; among those of potential
significance, especially with regards to gastric cancer, are the
cytotoxin-associated gene A (cagA), the cytotoxin-associated
gene T (cagT), the vacuolating cytotoxin gene (vacA), and
the outer inflammatory protein gene (oipA).
Both the cagA and cagT genes are located in the cag
pathogenicity island (cagPAI), a genetic locus that encodes
a type IV secretion system [50, 51]. Infection with cagA-
positive strains has been associated with higher degrees
of inflammation of the gastric mucosa; consequently, the
gene seems to play an important role in the development
of gastric cancer, being crucial to the formation of the
precancerous lesions present in cases of intestinal type gastric
adenocarcinoma [7, 9, 52, 53]. Upon delivery into host cells,
CagA protein leads to dephosphorylation of host cell proteins
and morphological changes in the cell [54, 55]. Additionally,
CagA has been shown to interfere with β-catenin signaling
[56, 57] and apical-junctional complexes [58], events that
have been linked to increased cell motility and oncogenic
transformation in a variety of models [51, 59, 60]. The cagT
gene, in turn, is a homologue of A. tumefaciens virB7, and its
role in the pathogenesis of gastrointestinal diseases has not
been completely ascertained. Nonetheless, this gene has been
considered an essential component in the IV secretion system
and has been associated with peptic ulcer disease [61] and
gastric cancer [62].
With respect to the VacA virulence factor, in addiction
to inducing vacuolation, it can induce multiple cellu-
lar activities, including membrane-channel formation and
cytochrome c release from mitochondria leading to apop-
tosis, and can bind to cell-membrane receptors, followed
by the initiation of a proinflammatory response; it can also
inhibit T-cell activation and proliferation [63–66]. The vacA
gene presents three regions—s (signal), I (intermediate), and
m (middle)—that have been associated with its cytotoxic
activity [67–69]. For instance, studies have reported that
individuals infected with s1 or m1 H. pylori strains have
an increased risk of peptic ulcer or gastric cancer compared
with individuals infected with s2 or m2 strains [70]. With
respect to the intermediate region, classified in i1 and i2, it
was shown that the i1 type is more pathogenic than i2 [69].
Finally, the OipA is an important virulence factor asso-
ciated with enhanced interleukin-8 secretion and increased
inflammation in vitro [71]. This gene is located in a
chromosomal region close to the cagPAI and is present
both as functional and nonfunctional. OipA functions as an
adhesive and is reported to be involved in the attachment of
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H. pylori to gastric epithelial cells in vitro [72, 73], playing
an important role in bacterial colonization. Its presence has
been associated with the increase of Interleukin-8 in gastric
cancer cells [74].
4.2.2. Host Susceptibility. Polymorphisms in a wide variety of
genes that are present within a significant proportion of the
normal population may modify the effect of environmen-
tal exposure. These gene-environmental interactions could
explain the high variation in the incidence of gastric cancer
observed around the world [75]. Among these genes, for
example, there are cytokine genes (TNF-α, IL-10, IL-8, and
IFN-γ) involved in the adaptive immune system [76, 77] and
pattern recognition factors (TLR-4, NOD-1, and NOD-2)
involved in initiating the innate immune system [78, 79].
Host-related factors for the development of disease can
indicate genetic susceptibility (or resistance) or acquired
influences, which may stimulate defenses of the host against
environmental carcinogens like H. pylori [80]. The relation-
ship between host genetic polymorphisms (for instance, in
the IL-1) and bacterial virulence factors appears to have a
crucial role in the development of the cancer, especially in
infections with cagA-positive, vacA s1m1, and oipA-positive
strains.
4.2.3. Environmental Factors. Environmental factors, par-
ticularly diet and smoking, play an important role in
the pathogenesis of gastric cancer. Diet rich in complex
carbohydrates, salt, pickled or smoked foods, dried fish, and
cooking oil has been linked with an increased risk, while diet
rich in fresh fruits and vegetables has been associated with a
low risk of gastric cancer [75, 81].
Smoking also represents an important factor in gastric
cancer development. A large study that included smoking
men demonstrated an increased risk for the development
of differentiated-type distal gastric cancer [82]. In Japan,
a study offered persuasive evidence that tobacco smoking
moderately increases the risk of gastric cancer among the
Japanese population [83]. Another study that analyzed forty-
two articles and compared current smokers and nonsmokers
provided solid evidence to classify smoking as the most
important behavioral risk factor for gastric cancer [84].
Finally, a recent study also concluded that smoking is an
important factor associated with the risk of developing
gastric cancer [85].
5. Eradication of H. pylori Infection and
Gastric Cancer
5.1. Can Reversion of Precancerous Lesions Be Achieved by H.
pylori Eradication? The risk of gastric cancer is related to
the severity and extent of atrophy, intestinal metaplasia, and
dysplasia; the main question concerning the development of
the cancer is whether eradication of H. pylori can reverse
these precancerous lesions and interrupt the process of gas-
tric carcinogenesis.
Two randomized studies, the first with a five-year follow-
up and the second with a one-year followup, observed that
H. pylori eradication was beneficial in preventing progression
of atrophy and intestinal metaplasia of the gastric mucosa
[86, 87]. Similarly, one study carried out in a high-risk popu-
lation suggested that effective anti-H. pylori treatment and
dietary supplementation with antioxidant micronutrients
may interfere with the precancerous process, mostly by
increasing the rate of regression of cancer precursor lesions,
and may be an effective strategy to prevent gastric carcinoma
[88].
Still, a long-term follow-up study found that preneoplas-
tic gastric lesions regress at a rate equal to the square of the
time in patients rendered free of H. pylori infection, which
also suggests that patients with preneoplastic gastric lesions
should be treated and cured of their H. pylori infection [89].
These results are supported by others, both retrospective and
prospective, that suggest that the eradication of H. pylori is
important to prevent the development of gastric cancer [90–
93].
However, despite a large number of studies demonstrat-
ing that H. pylori eradication has the potential to prevent
gastric cancer development, there is a limitation to this claim:
once preneoplastic changes have occurred, the prevention
of further progression of invasive cancer through H. pylori
eradication is less likely. One study carried out in 2004
was the first to indicate that bacterium eradication is not
a guarantee for preventing gastric cancer in patients with
chronic gastritis and existing preneoplastic changes [94].
Another critical aspect of the benefits of H. pylori
eradication in the prevention of gastric cancer development
is the timing for its occurrence. For instance, in a study
carried out in Japanese patients with peptic ulcer disease, the
incidence of gastric cancer was found to be 1.24% for those
receiving H. pylori eradication therapy and 2.56% for those
not, in a 5.6-year followup [95].
Consequently, it is obvious that there is a point of no
return, after which curing the H. pylori infection no longer
offers an effective prevention of gastric cancer [94, 96–98].
5.2. Eradication of H. pylori and Early Gastric Cancer: Is It
Important and Possible to Prevent the Cancer Recurrence?
For cancers detected early, endoscopic mucosal resection can
conserve the noncancerous gastric mucosa, but it cannot
eliminate the problem of recurrence of metachronous gastric
cancer [99]. A study published in 2008 [100] suggested
that prophylactic eradication of H. pylori in a high-risk
population can substantially reduce gastric cancer rates. In
this study, a randomized control trial following endoscopic
resection of early gastric cancer, a group of patients was
subjected to H. pylori eradication treatment and monitored
at different time intervals. At three years, metachronous
gastric cancer had developed in 9 of the 255 patients in the
eradication group, while, in the control group, these lesions
occurred in 24 of 250 patients.
However, not all treated patients benefited, although the
experimental data for humans are thin, they do support the
notion that H. pylori causes cancer and that its treatment
provides some benefit [98].
A very recent study carried out in patients with early-
stage gastric cancer demonstrates that H. pylori eradication
does not reduce the incidence of metachronous gastric
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cancer, bearing out that the eradication needs to be per-
formed before the progression of the atrophy of the gastric
mucosa [101]. Also emphasizing this aspect, another study
concluded that gastric cancer development after eradication
may have a carcinogenic pathway similar to that of cancer
with H. pylori infection though macroscopic/biological fea-
tures may be modified by the eradication therapy [102].
Results obtained from studies done with animal models
suggest that eradication at an early stage might be effective in
preventing carcinogenesis. Unfortunately, few of the animal
models had results comparable to those of humans, as they
were not infected for periods similar to those necessary for
the development of cancer in humans [103].
6. Conclusions
Understanding of gastric carcinogenesis has advanced con-
siderably over the past decades, especially with regards
to insights into the role of H. pylori infection and the
progression of chronic gastritis from premalignant stages to
gastric cancer. Based on the review presented here, although
controversy still remains as to whether eradication halts pro-
gression or can even cause regression of premalignant gastric
lesions, it can be concluded that eradication of H. pylori
infection has the potential to reduce the risk of gastric cancer
development. Furthermore, the optimal time to eradicate the
bacterium is before the development of preneoplastic lesions
such as atrophic gastritis and intestinal metaplasia. Along
with new therapeutic combinations, there is also a need to
identify subjects most at risk for cancer from their genetic
susceptibility and their infection with H. pylori genotypes
of greater carcinogenic potential. Finally, early diagnosis is
essential to ensure the best outcome of treatment, preventing
the development and the worsening of the gastric cancer.
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